Amphastar Pharmaceuticals' (AMPH) Hold (C-) Rating Reaffirmed at Weiss Ratings

Key Points

Error: Response status code does not indicate success: 503 (Service Unavailable).

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report)'s stock had its "hold (c-)" rating reiterated by equities researchers at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC raised shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 target price on the stock in a report on Tuesday, August 12th. Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a report on Friday, August 8th. Finally, Bank of America increased their price target on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a report on Tuesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $31.60.

Amphastar Pharmaceuticals Stock Up 0.6%

Shares of Amphastar Pharmaceuticals stock traded up $0.15 during trading hours on Wednesday, reaching $25.98. 250,038 shares of the company's stock were exchanged, compared to its average volume of 553,622. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The company has a 50 day moving average of $27.47 and a two-hundred day moving average of $25.49. The stock has a market cap of $1.21 billion, a P/E ratio of 9.73 and a beta of 0.75. Amphastar Pharmaceuticals has a fifty-two week low of $20.39 and a fifty-two week high of $53.96.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after acquiring an additional 424 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Amphastar Pharmaceuticals by 5.2% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company's stock valued at $217,000 after acquiring an additional 465 shares during the last quarter. Hohimer Wealth Management LLC raised its stake in shares of Amphastar Pharmaceuticals by 6.9% during the first quarter. Hohimer Wealth Management LLC now owns 8,005 shares of the company's stock valued at $232,000 after acquiring an additional 520 shares during the last quarter. Signaturefd LLC raised its stake in shares of Amphastar Pharmaceuticals by 147.7% during the first quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after acquiring an additional 520 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Amphastar Pharmaceuticals by 13.8% during the first quarter. PNC Financial Services Group Inc. now owns 4,783 shares of the company's stock worth $139,000 after buying an additional 580 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.